home - Sonata HCM

A CLINICAL STUDY TO EVALUATE SOTAGLIFLOZIN IN SYMPTOMATIC OBSTRUCTIVE AND NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

Help Shape the Future of HCM Treatment

Living with hypertrophic cardiomyopathy (HCM) can affect more than just your heart; it can impact your daily life, your plans, and the people around you.

By taking part in clinical research, you can help advance a potential new treatment that could make a difference for you and others living with HCM.

The study is currently enrolling.

Watch this video to see what taking part could look like and hear more about the study experience.

ABOUT THIS STUDY

This clinical study is investigating sotagliflozin, a once-daily dual-action SGLT1 & SGLT2 (Sodium-Glucose Co-Transporter) inhibitor, to see if it can improve symptoms of HCM. Earlier studies suggest it may lower the risk of heart failure events, heart attacks, and strokes.^1,2 Researchers are now assessing its potential benefits for people living with obstructive and non-obstructive HCM.

1. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117–128. doi:10.1056/NEJMoa2030183. 2. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129–139. doi:10.1056/NEJMoa2030186.

Why Take Part?

People take part in clinical studies for many different reasons. For some, it’s about exploring new possibilities. For others, it’s about helping future generations.

By participating, you could:

Contribute to research that may improve future HCM treatments
Help deepen understanding of this condition
Be part of progress that could benefit people living with HCM

What’s involved?

If you choose to take part, you will:

Attend a small number of study visits and phone check-ins
Receive either the study medication or a placebo (inactive treatment)
Be supported and monitored by a dedicated study team

Who’s eligible?

You may be eligible if you have been diagnosed with HCM and meet certain criteria, including:

Are 18 years or older
Have a stable heart condition – safe to participate in the study
Have certain blood sugar levels – with or without diabetes
Can take the study medication and attend visits

Important: A study doctor will review your medical history to confirm eligibility.

Now is a good time to explore whether taking part in the study could be right for you

Get in touch at SONATA-HCM@lexpharma.com to find a participating site near you.

Sotagliflozin is an investigational drug and is not currently approved for use by regulatory agencies like the FDA – its safety and effectiveness has not been established in HCM.